IASO Bio Receives U.S. FDA Approval Of Investigational New Drug Application For Equecabtagene Autoleucel For Two New Autoimmune Disease Indications

IASO Bio Raises Nearly $75 Million in Series C1 Funding

Fierce Biotech | China's IASO nets $108M to advance cell therapies, antibodies for cancer, autoimmune disease

PRECISIOIN ONCOLOGY NEWS: In Brief This Week-IASO Biotherapeutics, Genentech, BioNTech

Trailing the Big Pharma players, a lesser known BCMA CAR-T candidate comes into the spotlight

Bristol Myers Squibb and bluebird cleared the first BCMA CAR-T therapy for multiple myeloma patients back in March, and J&J and their partners at Legend Biotech aren’t far behind. Now, a lesser known candidate developed in China is coming into the spotlight at EHA.

IASO Bio to Present at ASH 2019

Nanjing, China., Nov 23, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma' (publication # 582) at American Society of Hematology, 61st ASH Annual Meeting & Exposition in Orlando, FL. on Dec. 7-10.

IASO Bio to Present at IMWG 2019

Nanjing, China., Sept 1, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Clinical Responses and Pharmacokinetics of fully human BCMA Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma' (abstract # 440) at 17th International Myeloma Workshop in Boston, MA. on Sept 12-15.